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Introduction
Colorectal cancer is the fourth leading cause of cancer and 
the second leading cause of cancer death in the U.S. each 
year. In the absence of distant metastatic disease, the status 
of the regional lymph nodes is the most powerful prognostic 
factor (1). Decisions regarding adjuvant chemotherapy and 
chemoradiotherapy are based, in large part, on the presence 
or absence of regional lymph node involvement. Given 
the importance of regional lymph node status, efforts to 
improve the accuracy of nodal staging are justified. The 
accuracy of lymph node staging improves as the number of 
lymph nodes pathologically examined increases (1). This 
observation, which has been made in both colon and rectal 
cancer, has led to consensus recommendations that at least 
12 lymph nodes be identified and subjected to histological 
examination in both colon and rectal cancer (2). This 
recommendation has gained strength, and an additional 
degree of importance, since the more recent publication 
of studies that demonstrate that survival after resection for 
colorectal cancer improves as the number of lymph nodes 
examined increases. Indeed, those evaluating the quality 
of care delivered in colon and rectal cancers are becoming 
interested in using this recommendation as a quality 
benchmark for both diseases (3,4).
This identical recommendation for minimum lymph 
node examination in both colon and rectal cancer seems to 
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Background: Recent publications have identified positive associations between numbers of lymph 
nodes pathologically examined and five-year overall survival (5-yr OS) in colon cancer. However, focused 
examinations of relationships between survival of rectal cancer and lymph node counts are less common. We 
conducted a single institution, retrospective review of rectal cancer resections to determine whether lymph 
node counts correlated with 5-yr OS and to explore the relationship between lymph node counts and various 
clinical and pathologic factors. 
Methods: A retrospective review of our institutional tumor registry identified 159 patients with AJCC Stage 
1, 2, or 3 rectal cancers that underwent surgical resection at our institution over eleven years. Univariate 
analysis was used to explore the relationship between lymph node counts and age, AJCC Stage, time period 
of diagnosis, preoperative radiotherapy, and performance of TME. Survival analysis was performed by the 
Kaplan-Meier method and the Cox proportional hazards model. 
Results: In univariate analysis, there was an association between increased lymph node counts and age <70,  
higher stage, and diagnosis during the later portion of the study period [all P-values <0.05]. Lymph node 
counts were not associated with survival in Kaplan-Meier analysis or in multivariate Cox proportional 
hazards analysis. 
Conclusions: Increasing lymph node counts improve survival and the accuracy of colorectal cancer 
staging. The body of literature recommends identical minimum lymph node counts in both colon and rectal 
cancer. In our study, which exclusively examined rectal cancer, we could not demonstrate that increased 
lymph node counts were associated with improved survival.
Key Words: Lymph node; rectal cancer; univariate analysis
Submitted Mar 05, 2013. Accepted for publication Apr 03, 2013.
doi: 10.3978/j.issn.2078-6891.2013.023
Scan to your mobile device or view this article at: http://www.thejgo.org/article/view/1067/html
159Journal of Gastrointestinal Oncology, Vol 4, No 2 June 2013
© Pioneer Bioscience Publishing Company. All rights reserved. J Gastrointest Oncol 2013;4(2):158-163www.thejgo.org
ignore two important points. It is generally understood that 
lymph node counts are consistently lower in rectal cancer 
specimens compared to colon cancer specimens. Second, 
the body of evidence supporting an association between 
higher lymph node counts and improved survival is heavily 
weighted to analyses of colon cancer rather than rectal 
cancer. Since the impact of lymph node counts in rectal 
cancer seems less clear, we performed a retrospective review 
to determine whether lymph node counts correlated with 
5-yr OS and to explore the relationship between lymph 
node counts and various clinical and pathologic factors.
Patients and methods
Through a search of our institutional tumor registry, we 
identified 190 patients with AJCC Stage 1, 2, or 3 rectal 
adenocarcinoma that underwent surgical resection in our 
hospital system over an eleven-year period (01/01/1995 
through 12/31/2005). Institutional Review Board approval 
was obtained to extract information from the database. 
We defined rectal cancer patients as those with an invasive 
tumor with its distal edge <15 cm from the anal verge. 
We excluded 28 patients treated by transanal excision and 
three that represented a recurrence from another primary 
diagnosed before the beginning of our study period. We 
then conducted a retrospective review of the medical 
records of the remaining 159 patients to develop a database 
containing standard clinico-pathologic variables. 
The clinico-pathologic data recorded included the 
following patient characteristics: age at diagnosis, gender, 
AJCC stage, histological grade, LNCs, period of diagnosis 
[1995-2000 and 2001-2005], administration of neoadjuvant 
therapy, and performance of a detailed mesorectal excision. 
LNCs were determined from the pathology report. For the 
purpose of analyses, LNCs were dichotomized in 4 different 
ways: ≥/<7, ≥/<10, ≥/<12, and ≥/<14, based on the median 
number of lymph nodes examined in the current study 
(i.e., 7) and values that appear in the literature (10, 12, and 
14) (3,5,6).
Univariate analysis (Kruskal-Wallis test) was used to 
explore the relationship between lymph node counts 
and the following variables: age (<70 yrs/>70 yrs), 
AJCC Stage ,  t ime  o f  d i agnos i s  ( ea r l y  — 1995-
2000/late — 2001-2005), gender, administration of 
neoadjuvant therapy and the performance of mesorectal 
excision. Five-year OS was estimated by the Kaplan-
Meier method and log rank testing was used to assess 
potential differences between groups. Cox proportional 
hazards modeling was used to examine the relationship 
between lymph node counts and survival, adjusting 
for patient age and stage at diagnosis. P-values ≤0.05 
were considered statistically significant.
Results
Age, stage at diagnosis, year of diagnosis, and performance 
of MRE were patient characteristics that were significantly 
associated with LNCs. Patients less than 70 years old had 
more lymph nodes retrieved compared to those ≥70 years 
old (P<0.05). In univariate analysis, there was no statistically 
significant difference in LNCs by gender or by the use of 
neoadjuvant therapy (P>0.05). Patients treated during the 
later years of the study were more likely to have more nodes 
retrieved (P>0.05). Patients with MRE performed had 
higher LNC, but not uniformly statistically significant for 
each cut point of LNCs used (Tables 1,2). 








Female 78 7 [3,10] 0.91
Male 81 8 [3,10]
Race
White 136 7 [3,10]
Black 20 9 [4,12] 0.43
Other 3 6 [5,9]
Age group
22-49 35 9 [5,14]
50-59 50 8 [5,11] 0.0004*
60-69 30 7 [3,9]
70+ 44 6 [0,8]
AJCC
I 87 5 [0,8]
II 28 8 [6,11] 0.0001*
III 44 10 [8,14]
Year of diagnosis
1995-2000 95 6 [2,9] 0.0079*
2001-2005 64 8 [6,11]
Pre-op XRT/chemo
No 133 7 [3,10] 0.7206
Yes 26 7 [4,10]
MRE
No 79 8 [5,11]
Yes 30 9 [7,12] 0.001*
N/A, missing, indet. 50 1 [0,7]
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In our survival analysis, we observed that higher LNCs 
were associated with lower survival rates. Although these 
differences in survival were not statistically significant, they 
were consistent for each cut point of LNCs used (Figure 1). 
In multivariate survival analysis using the Cox proportional 
hazards model, the apparent negative effect of increasing 
LNCs on survival did not persist. In this analysis, only Stage 
III disease and age over 70 yrs proved to be independent 
predictors of the risk of death (Table 3). The performance 
of MRE was not significant using the Cox proportional 
hazards model and subsequently not used in survival 
analysis.
Discussion
Colorectal cancer represents the second leading cause of 
cancer related death in the U.S., resulting in 55,000 deaths 
each year. In the absence of distant metastatic disease, 
the status of the regional lymph nodes is the single most 
powerful prognostic factor (1). The presence of lymph node 
involvement, when matched for similar T-stage, results in 
a decrease in 5-yr OS. Since the NIH consensus statement 
regarding adjuvant therapy for colon and rectal cancer 
was published in 1990, patients with node positive colon 
or rectal cancer generally have been offered a 5-FU based 
adjuvant chemotherapy regimen (7). The presence of nodal 
involvement also increases the risk of regional recurrence 
after rectal cancer resection, a risk that can be mitigated 
by pelvic 5-FU based chemoradiotherapy. Accordingly, 
Stage III rectal cancer patients are routinely offered such 
chemoradiotherapy as part of a curative treatment regimen. 
Given the importance of  lymph node status in 
determining prognosis and guiding treatment in colon 
and rectal cancer, accurate staging of these diseases is an 
important issue, both in the public health arena and for 
individual patients and their physicians. Multiple studies 
have demonstrated that the accuracy of staging in colorectal 
cancer improves when more lymph nodes are histologically 
examined (3,4). This fact, observed in both colon and 
rectal cancer, has led to consensus recommendations to 
identify and examine at least 12 lymph nodes from the 
resected colon or rectal cancer specimen (2). The interest 
in LNCs has escalated recently after the publication of a 
similar observation that the probability of survival after 
treatment for colon or rectal cancer improved in patients in 
whom more lymph nodes were histologically examined (8). 
Because of the relationship between LNCs and staging 
accuracy and LNCs and survival, minimum LNCs are an 
obvious target for those interested in evaluating the quality 
of care in colorectal cancer (3).
It is interesting that, in spite of the fact that there 
appear to be significant differences between colon cancer 
and rectal cancer, the minimum LNC recommendations 
do not discriminate between these two diseases (9). We 
believe that this is unfortunate, since considering these two 
disease as one disease process imprecisely characterizes 
each and ignores important differences between them (10). 
From an anatomical standpoint, the colon has a long 
abundant mesentery that contains vascular structures and 
rich lymphatics, while the rectal lymphatics are contained 
in a much more compact and shortened mesentery. In 
addition to these anatomic differences, the approaches to 
Table 2 Univariate analysis of patient characteristics by number of lymph nodes retrieved
Patient characteristics No. of Pts
No. [%] w/≥ 
7 nodes
No. [%] w/≥ 
10 nodes
No. [%] w/≥ 
12 nodes
No. [%] w/≥ 
14 nodes
Age at diagnosis
<70 yrs 115 72 [62.6] 43 [37.4] 23 [20.0] 18 [15.7]
≥70 yrs 44 19 [43.2] 5 [11.4] 1[2.3] 1 [2.3]
P-value ----- P=0.032* P=0.001* P=0.005* P=0.026*
AJCC stage
I 87 32 [36.8] 12 [13.8] 5 [5.8] 3 [ 3.5]
II 28 21 [75.0] 12 [42.9] 5 [17.9] 4 [14.3]
III 44 38 [86.4] 24 [54.6] 14 [31.8] 12 [27.3]
P-value ----- P<0.0001 * P<0.0001 * P=0.0003 * P=0.0002 *
Year of diagnosis
1995-2000 95 47 [49.5] 22 [23.2] 11 [11.6] 7 [7.4]
2001-2005 64 44 [68.8] 26 [40.6] 13 [20.3] 12 [18.8]
P-value ----- P=0.022* P=0.023* P=0.175 P=0.044*
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resecting the colon and rectal mesenteries differ. Standard 
teaching dictates that a 5 cm bowel wall margin is required 
on the proximal and distal ends of colon cancer resections. 
However, this bowel margin is never a practical issue as 
colon resections are based on the segmental, mesenteric 
blood supply and lymphatic drainage of the part of the 
colon to be resected. In rectal cancer resections, the 
technical considerations are more complicated. While 
most agree that the proximal bowel margin should be at 
least 5 cm, the acceptable distal margin has been a source 
of some disagreement/confusion (11). Historically, a 2 cm 
distal margin on the bowel wall was considered adequate. 
However, since Heald described the total mesorectal 
excision in 1982, there has been a growing recognition that 
the distal margin of importance in rectal resections is the 
one on the mesorectum, and that this should be at least 4 cm 
distal to the tumor (12). Our study suggests that attention to 
the distal mesorectal margin might be suboptimal, as TME 
was described in a minority of cases in our series. If this is 
true of community practice in general, this combination 
of mesenteric anatomic facts and differences in common 
surgical techniques for mesenteric resection might explain 
the gap in LNCs observed between colon cancer and rectal 
cancer resections. It also makes a compelling argument for 
A B
C D
Figure 1 Kaplan-Meier estimates of 5-year overall survival by No. of lymph nodes retrieved
Table 3 Cox proportional hazards modeling controlling for age 
and stage at diagnosis
Factor Hazard ratio [95% CI] P-value
Age at diagnosis
<70 yrs Referent group -----
≥70 yrs 5.47 [2.79,10.70] 0.0001*
Stage at diagnosis
1 Referent group -----
2 2.06 [0.78,5.46] 0.146
3 4.16 [1.80, 9.62] 0.0009*
Lymph node comparisons
≥7 vs. <7 0.99 [0.48,2.04] 0.97
≥10 vs. <10 1.13 [0.54,2.38] 0.74
≥12 vs. <12 0.93 [0.39,2.26] 0.88
≥14 vs. <14 0.98 [0.38,2.49] 0.96
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additional studies that attempt to more clearly characterize 
both the operative treatment of rectal cancer and the impact 
this treatment has on outcome measures, such as LNCs, OS 
and regional recurrence. 
This consistent gap in LNCs between colon cancer and 
rectal cancer makes it logical to pursue separate minimum 
LNCs for each disease. Since we understand that more 
appears to always be better when it comes to staging, we are 
not necessarily arguing to decrease the minimum for LNCs 
in rectal cancer. It might actually be more reasonable, 
however, to increase the minimum LNCs for colon cancer. 
This would then create some distinction between colon 
and rectal cancer that reflects the current data. It might 
also give those involved in quality oversight efforts a better 
perspective on what constitutes an acceptable and fair 
quality benchmark for LNCs in rectal cancer. It is also 
worthwhile to remember the LNC is not the only factor in 
determining outcomes after rectal cancer treatment (13). 
Ultimately, lymph node count will be but one of many 
factors considered in this disease. Because of the ease 
of determination of LNCs, however, and the described 
relationship between LNCs and survival, LNCs now 
occupy a central place in the discussion. 
In an effort to better understand the factors that affect 
LNCs in rectal cancer, we explored the relationship between 
LNCs and several clinico-pathologic factors. While gender 
and race did not appear to affect LNCs, patient age did 
seem to affect LNCs, as patients under 70 had higher LNCs 
than those over 70. In addition, the period of diagnosis 
was also important, as patients in our cohort diagnosed 
after 2000 had higher LNCs. While this suggests some 
change over time, we cannot readily identify the source of 
that change. We suspect that increased awareness among 
treating physicians and pathologists might have contributed 
to the improvement in LNCs. 
Another potential explanation for the increase in LNCs 
could be a shift in the operative techniques being employed. 
We did not observe any increase in the frequency of 
TME performance but noticed an increase in LNCs in 
those patients undergoing a TME. As suggested earlier, 
we believe the impact of surgical techniques of rectal 
resection on LNCs deserves more attention. Unfortunately, 
larger, population-based data sets do not provide this 
level of detail. Another potentially important factor in 
rectal cancer and LNCs is the delivery of preoperative, 
pelvic radiotherapy. Neoadjuvant radiotherapy is known 
to decrease LNCs in the resected rectal cancer specimen. 
Since neoadjuvant chemoradiotherapy has been accepted as 
a standard treatment for node positive and Stage II rectal 
cancers, efforts to use LNCs as a quality indicator will have 
to consider the impact of this approach on this metric. 
One would assume that minimum LNCs would necessarily 
be adjusted downward. Other clinical factors, such as the 
clinical and or pathologic response to the preoperative 
therapy might also have an impact on LNCs. Prior 
studies have not considered patients who had undergone 
neoadjuvant therapy (14,15). In the current study, there did 
not appear to be any difference in LNCs between patients 
who received preoperative chemoradiotherapy and those 
who did not. One possible explanation for this negative 
result might be that more patients received neoadjuvant 
chemoradiatherapy in the later period, during which LNCs 
increased. It is possible, therefore, that the negative impact 
on LNCs expected because of preoperative radiotherapy 
was masked by improved identification during the later 
period of the study. Another possible explanation is that 
our study simply lacked the power to detect a difference 
in LNCs caused by preoperative radiotherapy. In either 
case, future population-based studies should attempt 
to characterize LNCs in patients who have undergone 
preoperative radiotherapy and to determine whether LNCs 
in this clinical setting carry the same importance as they 
appear to carry in untreated patients. 
While the improvement in staging accuracy with 
increasing LNCs has been firmly established, the 
relationship between lymph node counts and survival is 
less settled. In the current study, no statistically significant 
improvement in 5-yr OS was detected with increasing 
LNCs. In fact, in Kaplan Meier analysis, higher lymph node 
counts correlated with worse survival, albeit not statistically 
significant either. This consistent observation, regardless 
of how LNCs were dichotomized, is likely because 
increasing LNCs were closely correlated with increasing 
stage. It is difficult to imagine, based on the current data, 
that an improvement in survival could be observed as 
LNCs increase, since increasing LNCs are so closely tied 
to increasing stage, and increasing stage is itself tied to 
worse OS. We recognize that our inability to demonstrate 
an improvement in survival with increasing LNCs does 
not preclude the existence of such a relationship. In fact, 
larger studies have provided more definitive information 
on this relationship (5,15). It is worth pointing out that 
large studies like these are crucial in detecting such 
phenomena since institutionally based studies would be 
much less likely to uncover them. Patient-level studies 
remain important; however, because they provide more 
granular clinical data that when analyzed teases out the why 
and the how behind observations from population-based 
studies. Combining individual institutional studies should 
improve the productivity of this type of study. Perhaps the 
most important role of these patient-level studies could be 
to inform and improve the population-based registries by 
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suggesting which additional data should be collected by 
these organizations.
The current study examines the relationship between 
LNCs in resected rectal cancer and various clinico-
pathologic factors. Higher LNCs were associated with 
younger age, higher stage, diagnosis in the later period 
of our study, and performance of MRE. We could not 
demonstrate a decrease in lymph node counts among 
patients treated with neoadjuvant chemoradiotherapy. 
Examination of the relationship between lymph node counts 
and 5-yr OS failed to demonstrate any improvements in 
survival with higher LNCs. In fact, the opposite effect 
of higher LNCs was observed. Based on the apparent 
differences between rectal cancer and colon cancer, we 
believe separate recommendations for minimum lymph 
node counts should be developed, based on population-
based data. We also believe that LNCs in patients treated 
with preoperative chemoradiotherapy should be separately 
analyzed to determine appropriate quality benchmarks. 
Finally, recalling that LNC is not the only important factor, 
institutionally based studies should continue to identify 
other factors that influence outcomes after rectal cancer 
treatment. These factors could then be considered for 
inclusion in the data collection efforts of large population-
based registries.
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